<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6319">
  <stage>Registered</stage>
  <submitdate>10/11/2014</submitdate>
  <approvaldate>10/11/2014</approvaldate>
  <nctid>NCT02289690</nctid>
  <trial_identification>
    <studytitle>Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer</studytitle>
    <scientifictitle>A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Na√Øve Extensive Stage Disease Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-001764-35</secondaryid>
    <secondaryid>M14-361</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Veliparib
Treatment: drugs - Carboplatin
Treatment: drugs - Etoposide

Experimental: Veliparib and carboplatin and etoposide - Veliparib in combination with carboplatin/etoposide followed by veliparib monotherapy

Experimental: Veliparib and carboplatin and etoposide and placebo - Veliparib in combination with carboplatin/etoposide followed by placebo monotherapy

Placebo Comparator: Placebo and Carboplatin and etoposide - Placebo in combination with carboplatin/etoposide followed by placebo monotherapy


Treatment: drugs: Veliparib
Varying doses administered on Days -2 to 5 in a 21-day cycle

Treatment: drugs: Carboplatin
Administered on Day 1 via intravenous infusion in a 21-day cycle

Treatment: drugs: Etoposide
Administered on Days 1 to 3 via intravenous infusion in a 21-day cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with carboplatin and etoposide</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Recommended Phase 2 dose of veliparib (ABT-888) in combination with carboplatin and etoposide</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of adverse events during maintenance veliparib monotherapy at 400 mg twice daily (BID)</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subject with histologically or cytologically confirmed extensive-stage disease SCLC
             which is newly diagnosed and chemotherapy naive

          2. Phase 1 ONLY: histologically or cytologically confirmed advanced/metastatic solid
             tumors for which carboplatin/etoposide treatment is considered appropriate.

          3. Subject in Phase 2 only: must have measurable disease per RECIST 1.1.

          4. Subjects with ED SCLC must consent to provide available archived formalin fixed
             paraffin embedded (FFPE) tissue sample of SCLC lesion (primary or metastatic) for
             central review and biomarker analysis.

          5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.

          6. Subject must have adequate hematologic, renal and hepatic function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Phase 1 ONLY: Subject has had any prior anti-cancer therapy other than:

             Hormonal, non-myelosuppressive, biologic, targeted, or immune therapy (must be
             completed = 4 weeks prior to Cycle 1 Day -2).

             One line of cytotoxic chemotherapy (must be completed = 4 weeks prior to Cycle 1 Day
             -2).

             Adjuvant/neoadjuvant radiotherapy (must be completed = 12 months prior to Cycle 1 Day
             -2, with field not involving &gt; 10% of bone marrow reserve).

          2. Phase 2 ONLY: Subject has had any prior chemotherapy, radiotherapy, investigational
             anti-cancer agents or biologic therapy for the disease under study. Single non-target
             lesion irradiation with intent of symptom palliation is allowed if = 4 weeks prior
             Cycle 1 Day -2.

          3. Subject has current central nervous system (CNS) or leptomeningeal metastases or
             history of CNS or leptomeningeal metastases.

          4. Subject has a history of seizures within 12 months of Cycle 1 Day-2 or diagnosed
             neurological condition placing subject at the increased risk of seizures.

          5. Subject has received anti-cancer Chinese medicine or anti-cancer herbal remedies
             within 14 days prior to Cycle 1 Day-2.

          6. Subject has had major surgery within 6 weeks prior to Cycle 1 Day-2 (subjects must
             have completely recovered from any previous surgery prior Cycle 1 Day-2).

          7. Subject has clinically significant and uncontrolled major medical condition(s)
             including but not limited to:

               -  Uncontrolled nausea/vomiting/diarrhea;

               -  Active uncontrolled infection;

               -  History of hepatitis B (HBV) with surface antigen (HBsAg) positivity within 3
                  months prior to the date of informed consent for this study (if no test has been
                  performed within 3 months, it must be done at screening);

               -  History of hepatitis C (HCV) with HCV RNA positivity within 3 months prior to the
                  date of informed consent for this study (if no test has been performed within 3
                  months it must be done at screening);

               -  Symptomatic congestive heart failure (NYHA class = II);

               -  Unstable angina pectoris or cardiac arrhythmia (except atrial fibrillation);

               -  Psychiatric illness/social situation that would limit compliance with study
                  requirements;

               -  Any other medical condition, which in the opinion of the Investigator, places the
                  subject at an unacceptably high risk for toxicities.

          8. The subject has a history of another active cancer within the past 3 years except
             cervical cancer in situ, in situ carcinoma of the bladder, squamous or basal cell
             carcinoma of the skin or another in situ cancer that is considered cured by the
             investigator (e.g., in situ prostate cancer, breast DCIS).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>13/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>215</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>27/03/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Border Medical Oncology Research Unit /ID# 157894 - Albury</hospital>
    <hospital>The Townsville Hospital and Health Services /ID# 155499 - Douglas</hospital>
    <hospital>Peninsula &amp; South Eastern Haematology and Oncology /ID# 155497 - Frankston</hospital>
    <hospital>Southern Medical Day Care Center /ID# 155498 - Wollongong</hospital>
    <postcode>2640 - Albury</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>2500 - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mons</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Namur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Nova Ves Pod Plesi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Novy Jicin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Farkasgyepu Kulterulet</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Matrahaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szekesfehervar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szolnok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szombathely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Chungcheongbuk-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeonnam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Harderwijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Heerlen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Belgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Murmansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saransk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid (Espana)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda, Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin
      and etoposide in participants with extensive disease small cell lung cancer (ED SCLC). ED
      SCLC is defined herein as any SCLC except a disease confined to the hemithorax of origin,
      with or without the involvement of regional lymph nodes, including ipsilateral and
      contralateral mediastinal, ipsilateral and contralateral mediastinal, and ipsilateral
      supraclavicular nodes</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02289690</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Philip Komarnitsky, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Abbvie Oncology Clinical Trial Navigation Service</name>
      <address />
      <phone>844-893-5525</phone>
      <fax />
      <email>Abbvie@emergingmed.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>